IP Library Granted Patent US 11,046,996
Granted Patent B1
US 11,046,996 · App. 17/180,356 · Granted Jun 29, 2021

Methods and systems for determining spatial patterns of biological targets in a sample

Inventors: Mark S. Chee (San Diego, CA); David A. Routenberg (San Diego, CA)
Assignee: Prognosys Biosciences, Inc.
C12Q1/6809B01L3/5027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,996
App. No.
17/180,356
Granted
Jun 29, 2021
Kind
B1
Abstract

The present disclosure provides methods and assay systems for use in spatially encoded biological assays, including assays to determine a spatial pattern of abundance, expression, and/or activity of one or more biological targets across multiple sites in a sample. In particular, the biological targets comprise proteins, and the methods and assay systems do not depend on imaging techniques for the spatial information of the targets. The present disclosure provides methods and assay systems capable of high levels of multiplexing where reagents are provided to a biological sample in order to address tag the sites to which reagents are delivered; instrumentation capable of controlled delivery of reagents; and a decoding scheme providing a readout that is digital in nature.

Claims (39)

1. A system for determining the presence and/or location of a target protein in a sample, the system comprising:

(a) a plurality of first probes, wherein a first probe of the plurality of first probes comprises: (i) a binding moiety that specifically binds to the target protein, and (ii) an oligonucleotide conjugated to the binding moiety;

(b) a plurality of second probes, wherein a second probe of the plurality of second probes comprises: (i) a sequence substantially complementary to a portion of the oligonucleotide of step (a), (ii) a first address tag that identifies a first area in the sample, and (iii) a first ligation region;

(c) a plurality of third probes, wherein a third probe of the plurality of third probes comprises: (i) a second address tag that identifies a second area in the sample, and (ii) a second ligation region;

(d) a first microfluidic device comprising multiple first addressing channels, wherein the second probe is delivered through a first addressing channel of the multiple first addressing channels; and

(e) a second microfluidic device comprising multiple second addressing channels, wherein the third probe is delivered through a second addressing channel of the multiple second addressing channels.

2. The system of claim 1 , wherein the multiple first addressing channels are substantially parallel to each other and the multiple second addressing channels are substantially parallel to each other.

3. The system of claim 1 , wherein the multiple first addressing channels and/or the multiple second addressing channels is n addressing channels, wherein n is an integer between 20 and 1000.

4. The system of claim 1 , wherein the width of each of the multiple first addressing channels and/or each of the multiple second addressing channels is about 1 μm to about 500 μm.

5. The system of claim 1 , wherein the depth of each of the multiple first addressing channels and/or each of the multiple second addressing channels is about 1 μm to about 500 μm.

6. The system of claim 1 , wherein the distance between each of the multiple first addressing channels and/or between each of the multiple second addressing channels is about 1 μm to about 2.0 mm.

7. The system of claim 1 , wherein the second area forms an angle with the first area at an intersection between the first area and the second area, and wherein the angle is about 10 degrees to about 90 degrees.

8. The system of claim 1 , wherein the third probe further comprises a variable tag region, a primer sequence, a sequencing adaptor, a biotin moiety, or a combination thereof.

9. The system of claim 1 , further comprising a splint oligonucleotide, wherein the splint oligonucleotide is substantially complementary to all or a portion of the first ligation region and all or a portion of the second ligation region.

10. The system of claim 1 , wherein the binding moiety comprises an antibody or an antigen binding fragment thereof, an aptamer, a small molecule, an affinity capture agent, or a combination thereof.

11. The system of claim 1 , wherein the sample is a freshly isolated tissue sample, a fixed tissue sample, a frozen tissue sample, an embedded tissue sample, a processed tissue sample, or a combination thereof.

12. The system of claim 1 , further comprising one or more enzymes selected from a polymerase, a reverse transcriptase, or a ligase.

13. The system of claim 1 , further comprising a module for imaging the sample.

14. The system of claim 1 , wherein the system further determines the presence and/or location of a target polynucleotide, and wherein the sequence substantially complementary to a portion of the oligonucleotide of step (a) is substantially complementary to at least a portion of the target polynucleotide.

15. The system of claim 14 , wherein the target polynucleotide is an RNA molecule.

16. The system of claim 15 , wherein the RNA molecule is an mRNA molecule.

17. The system of claim 14 , wherein the portion of the target polynucleotide is a poly(A) sequence.

18. A system for determining the presence or location of a target polynucleotide in a sample, the system comprising:

(a) a plurality of first probes, wherein a first probe of the plurality of first probes comprises: (i) a sequence substantially complementary to at least a portion of the target polynucleotide, (ii) a first address tag that identifies a first area in the sample, and (iii) a first ligation region;

(b) a plurality of second probes, wherein a second probe of the plurality of second probes comprises: (i) a second address tag that identifies a second area in the sample and (ii) a second ligation region;

(c) a first microfluidic device comprising multiple first addressing channels, wherein the first probe is delivered through a first addressing channel of the multiple first addressing channels to the first area; and

(d) a second microfluidic device comprising multiple second addressing channels, wherein the second probe is delivered through a second addressing channel of the multiple second addressing channels to the second area.

19. The system of claim 18 , wherein the multiple first addressing channels are substantially parallel to each other and the multiple second addressing channels are substantially parallel to each other.

20. The system of claim 18 , wherein the multiple first addressing channels and/or the multiple second addressing channels is n addressing channels, wherein n is an integer between 20 and 1000.

21. The system of claim 18 , wherein the width of each of the multiple first addressing channels and/or each of the multiple second addressing channels is about 1 μm to about 500 μm.

22. The system of claim 18 , wherein the depth of each of the multiple first addressing channels and/or each of the multiple second addressing channels is about 1 μm to about 500 μm.

23. The system of claim 18 , wherein the distance between each of the multiple first addressing channels and/or between each of the multiple second addressing channels is about 1 μm to about 2.0 mm.

24. The system of claim 18 , wherein the second area forms an angle with the first area at an intersection between the first area and the second area, and wherein the angle is about 10 degrees to about 90 degrees.

25. The system of claim 18 , wherein the second probe further comprises a variable tag region, a primer sequence, a sequencing adaptor, a biotin moiety, or a combination thereof.

26. The system of claim 18 , further comprising a splint oligonucleotide, wherein the splint oligonucleotide is substantially complementary to all or a portion of the first ligation region and all or a portion of the second ligation region.

27. The system of claim 18 , wherein the target polynucleotide is an mRNA molecule.

28. The system of claim 18 , wherein the sample is a freshly isolated tissue sample, a fixed tissue sample, a frozen tissue sample, an embedded tissue sample, a processed tissue sample, or a combination thereof.

29. The system of claim 18 , further comprising one or more enzymes selected from a polymerase, a reverse transcriptase, or a ligase.

30. The system of claim 18 , further comprising a module for imaging the sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2021
From: CHEE, MARK S.; ROUTENBERG, DAVID A.
To: PROGNOSYS BIOSCIENCES, INC.
Reel/Frame 055444/0304 →
Continuity (6)
Continuation 16986922 · Aug 6, 2020
Continuation 16596200 · Oct 8, 2019
Continuation 15831158 · Dec 4, 2017
Continuation 14900604
Provisional Application 61839320 · Jun 25, 2013
Provisional Application 61839313 · Jun 25, 2013
Cited By (45)
US 12,195,790 US 12,203,134 US 12,209,280 US 12,223,751 US 12,228,544 US 12,234,505 US 12,241,060 US 12,241,890 US 12,249,085 US 12,265,079 US 12,270,077 US 12,275,988 US 12,281,357 US 12,286,673 US 12,287,264 US 12,297,486 US 12,297,487 US 12,297,488 US 12,344,892 US 12,365,935 US 12,365,942 US 12,371,688 US 12,378,607 US 12,385,083 US 12,391,979 US 12,391,980 US 12,399,123 US 12,404,544 US 12,405,264 US 12,416,603 US 12,435,363 US 12,442,045 US 12,497,654 US 12,508,590 US 12,529,094 US 12,545,949 US 12,553,805 US 12,553,898 US 12,566,113 US 12,566,114 US 12,571,029 US 12,624,475 US 12,637,706 US 12,668,835 US 12,692,492